Summary: Water reabsorption in the kidney represents a critical physiological event in the maintenance of body water homeostasis. This highly regulated process relies largely on vasopressin (VP) action and on the VP-sensitive water channel (AQP2) that is expressed in principal cells of the kidney collecting duct. Defects in the VP signaling pathway and/or in AQP2 cell surface expression can lead to an inappropriate reduction in renal water reabsorption and the development of nephrogenic diabetes insipidus, a disease characterized by polyuria and polydipsia. This review focuses on the major regulatory steps that are involved in AQP2 trafficking and function. Specifically, we begin with a discussion on VP-receptor-independent mechanisms of AQP2 trafficking, with special emphasis on the nitric oxide-cyclic guanosine monophosphate signaling pathway, followed by a review of the mechanisms that govern AQP2 endocytosis and exocytosis. We then discuss emerging data illustrating roles played by the actin cytoskeleton on AQP2 trafficking, and lastly we consider elements that affect AQP2 protein expression in cells. Recent advances in each topic are summarized and are presented in the context of their potential to serve as a basis for the development of novel therapies that may ultimately improve life quality of nephrogenic diabetes insipidus patients.

Water homeostasis and urine concentration via water reabsorption in the urinary tubule are integral functions of the kidney. In normal human subjects, the glomerular system can filter 180 L/d of fluid, of which 90% is reabsorbed back into the circulat-
expression and whole-cell abundance of the aquaporin-2 (AQP2) water channel in CD principal cells. The most severe forms of NDI are observed in congenital cases, in which patients most often harbor mutations in the vasopressin type-2 receptor (V2R) gene, although a small percentage (10%) bear recessive or autosomal-dominant mutations in the AQP2 gene.1

The release of VP, a cyclic nonapeptide hormone secreted by the posterior pituitary gland, is regulated in the brain in response to serum osmolality and body volume status. In the presence of high serum osmolality or hypovolemia, VP is released into the blood stream where it binds to V2R expressed on the basolateral surface of CD principal cells. V2R is a G-protein-coupled receptor, and VP binding initiates the V2R signaling cascade, inducing a conformational change that promotes G,α dissociation, adenylyl cyclase activation, and consequently an increase in intracellular cyclic adenosine monophosphate (cAMP) levels. The classical view of AQP2 trafficking, based on the so-called “shuttle hypothesis” originally proposed to explain water channel trafficking in the toad urinary bladder,2 postulates that an increase in cAMP concentration and ensuing activation of protein kinase type A (PKA) leads to the phosphorylation of AQP2 by PKA and subsequently altering the balance between exocytosis and endocytosis, leading to AQP2 accumulation at the apical plasma membrane.2

The figure illustrates the interactions between the components of some of the major pathways that affect AQP2, and summarizes most of the points outlined in this review. The canonical V2R signaling pathway is depicted, with VP stimulation of V2R leading to the phosphorylation of AQP2 by PKA and subsequently altering the balance between exocytosis and endocytosis, leading to AQP2 accumulation at the apical plasma membrane. Also shown are the NO-cGMP pathway and the PGE2 receptor EP3 that can also positively and negatively modulate AQP2 trafficking, respectively, as well as factors that affect AQP2 abundance and the elements and transcription factors that mediate this regulation. AP1, activator protein-1 element; AC, adenylyl cyclase; CREB, CRE binding protein; G,α, G-protein iα subunit; G,β, G-protein sα subunit; GC, guanylate cyclase; MAL, myelin and lymphocyte-associated protein; NFATc, nuclear factor of activated T-cells c; Rho, Rho family small GTPase.
AQP2 at the apical membrane leads to an influx of water into the cell driven by the interstitial osmotic gradient generated by urea and sodium chloride. Water then exits the cell via AQP3 and AQP4 water channels located at the basolateral side of the cell, allowing its re-entry into the interstitium and the circulatory system.

Polyuria in acquired NDI can be partially reduced by a combination of treatments such as adequate hydration, low-salt and/or low-protein diet, diuretics, and nonsteroidal anti-inflammatory drugs. However, congenital patients often respond poorly to such therapies. Some studies have focused on rescuing misfolded V2R by developing nonpeptidic lipid-soluble vasopressin ligands that cross the plasma membrane and reach misfolded receptors trapped in the endoplasmic reticulum. The ligand acts like a molecular chaperone, helping V2R refold, escape the endoplasmic reticulum quality control, and reach the plasma membrane where endogenous VP can subsequently displace the VP analogue and activate the receptor. These compounds have shown some positive effects on patients bearing specific missense mutations or small insertion/deletion V2R mutations, but are not effective against truncated proteins, and furthermore, they did not alleviate polyuria completely. A second strategy has used aminoglycoside antibiotics such as gentamicin. This class of antibiotics causes read-through of some nonsense V2R mutations in vitro and in vivo, but the beneficial effect of aminoglycosides unfortunately is overshadowed by its toxicity to the kidneys. Another disadvantage of attempts at rescuing mutant receptors is that they often are heavily dependent on the nature of the mutation and, therefore, any such therapy may not be widely applicable. Finally, the use of cAMP phosphodiesterase (PDE) inhibitors such as rolipram has so far been unsuccessful for the treatment of NDI. Although beneficial effects have been observed in mouse models, they have not been reproduced in human subjects, perhaps reflecting a difference in cAMP PDE localization.

The search for more effective therapeutic strategies for both acquired and congenital NDI has, thus, motivated many advances in our understanding of the V2R signaling cascade that regulates AQP2 trafficking. In addition, various other physiological factors that modulate AQP2 cell-surface localization as well as its abundance are now beginning to be uncovered. In this review, we begin by describing the V2R-independent nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) pathway and recent studies that have linked this important signaling cascade to AQP2 shuttling. We then discuss the use of PDE inhibitors such as Viagra as potential therapeutic agents. Next, we summarize novel developments on the role of endocytosis on AQP2 trafficking and consider plausible targets for bypassing V2R, as well as the possibility of using statins in NDI treatment. Finally, we provide a brief overview of other signaling pathways currently being investigated that regulate AQP2 abundance and that may be explored in the future in the search for specific targets that can be readily exploited in novel therapeutic strategies in the treatment of NDI, as well as other forms of water imbalances.

THE NO-cGMP SIGNALING PATHWAY

Together with the canonical cAMP-induced pathway, the NO-cGMP signaling pathway has been shown to play a role in AQP2 trafficking, prompting investigation of this signaling pathway as a means to develop alternative therapies for treatment of NDI. NO is a free radical resulting from the enzymatic conversion of L-arginine to L-citrulline by 1 of 3 isoforms of NO synthetase (NOS) expressed in the kidney. NO produced by endothelial NOS (eNOS), inducible NOS, and neuronal NOS can diffuse and, therefore, act in both an autocrine and paracrine fashion in the kidney. The classic NO signaling pathway depends on activation of soluble guanylate cyclase, located in several segments of the nephron including the CD, where it is expressed in principal cells. The major effect of an increase of cGMP concentration is cGMP-dependent protein kinase (PKG) activation. However, cGMP also affects PKA and p21ras kinase activity and can directly regulate Na-channel and glucose transporter (GLUT4) activity, as well as trafficking of type 1 and type 5 water channels (AQP1 and 5). All components of the NO-cGMP signaling pathway are expressed in renal epithelial cells, supporting the notion that the...
NO-cGMP signaling pathway plays a key role in principal cell physiology, including fluid transport in the kidney.

The effect of NO-cGMP in CD water reabsorption still is controversial. In one study, NO donors were found to decrease VP-induced water reabsorption as a consequence of reduced osmotic water permeability and sodium reabsorption, whereas another report failed to observe this inhibitory effect.\(^{17,18}\) Another study showed that NO antagonizes the effect of VP by altering cAMP levels.\(^{19}\) In our hands, VP increased the conversion of L-arginine to L-citrulline. However, increased NOS activity appears to result from an indirect effect and VP may simply increase substrate availability. Nevertheless, increasing evidence supports the idea that NO-cGMP is involved in renal water reabsorption. VP increases neuronal NOS and eNOS expression in water-deprived rats, and eNOS expression is accompanied by a reduction of urine output, suggesting that it plays a role in water homeostatic mechanisms.\(^{20,21}\) Simultaneous disruption of all 3 NOS isoforms led to NDI in mice\(^{22}\) and a reduction of AQP2 whole-cell abundance. The mechanism that regulates AQP2 abundance still is elusive, but may be related to low cAMP intracellular levels detected in knock-out mice owing to increased prostacyclin activity.\(^{22}\) A reduction of basal intracellular cGMP concentration owing to the absence of NOS may lead to decreased levels of functional PKG that subsequently may affect cAMP-response-element (CRE)-dependent transcription.\(^{23}\) Thus, AQP2 expression, which is regulated chiefly by VP, may be stimulated additionally by NOS basal activity. This may partially explain the significant amount of AQP2 expression in Brattleboro rats, which do not express circulating VP.

Our study provided evidence that both sodium nitroprusside, a NO donor, and L-arginine, a precursor of NO, are able to shift the localization of AQP2 from the cytoplasm to the apical side of rat CD principal cells.\(^{24}\) This increase of AQP2 membrane insertion was cGMP-dependent but cAMP-independent. The role of cGMP in AQP2 trafficking was confirmed by analysis of the atrial natriuretic peptide receptor, which has intrinsic guanylate cyclase activity, and by analysis of the effects produced by the cell-permeant dibutylr cGMP analogue. Both agents induced translocation of AQP2 to the plasma membrane. In addition, atrial natriuretic peptide infusion in rat induced a marked increase in AQP2 apical targeting.\(^{25}\) The mechanism by which cGMP induces AQP2 trafficking still is unclear. Our study showed that AQP2 can be phosphorylated by PKG, but we cannot reasonably eliminate the possibility that PKG phosphorylates PKA, nor can we yet rule out that an increase of cGMP concentration activates PKA and subsequently induces an accumulation of AQP2 at the plasma membrane.

**VIAGRA STIMULATES AQP2 TRAFFICKING**

Because cGMP increases AQP2 membrane insertion in rat kidney, we investigated the effect of selective cyclic-3’,5’-nucleotide PDE inhibitors, which abolish cGMP catabolism and subsequently increase cGMP concentration, on AQP2 cell surface expression. Intracellular cAMP and cGMP levels are regulated strongly by one or more members of 11 PDE families that together account for more than 60 isoforms. Several isoforms are expressed along the nephron, such as cAMP-sensitive PDEs (PDE 3 and 4), cGMP-sensitive PDE (PDE 5), and cAMP/cGMP-selective PDE (PDE 1). We used sildenafil citrate (Viagra), a selective cGMP phosphodiesterase (PDE5) inhibitor, as a means to increase intracellular cGMP concentration. Sildenafil has been used successfully in clinical treatment of erectile dysfunction. We studied the effect of PDE5 inhibition on AQP2 trafficking in LLC-PK1 renal epithelial cells expressing c-myc–tagged AQP2. Western blot analysis showed that the presence of sildenafil or 3-isobutyl-1-methylxanthine (IBMX), a nonselective cAMP/cGMP PDE inhibitor, enhanced AQP2 expression at the plasma membrane (Fig. 2A).\(^{26}\) We also observed that both PDE5 inhibitors sildenafil and 4-(3’,4’-(methylenedioxy)benzyl)amino)-6-methoxyquinazoline modulate endogenous AQP2 trafficking in rat kidney (Fig. 2B).\(^{24}\) Sildenafil increased insertion of AQP2 in the apical membrane of principal cells of outer medullary CD both in vitro and in vivo, but did not have an effect on AQP2 localization in cortical CD, a major site of water reabsorption.\(^{26}\) Although our studies suggest that PDE inhibition may
offer a promising approach for X-linked NDI therapy, further studies need to be performed to determine whether prolonged cGMP inhibition, or a combined therapeutic approach, can improve water reabsorption in patients suffering from NDI who may express variable amounts of AQP2 in their principal cells.

AQP2 ENDOCYTOSIS AND EXOCYTOSIS

About 10% of congenital NDI cases are associated with AQP2 mutations rather than with defects of V2R signaling. Interestingly, the majority of these mutations are manifested as misrouting errors rather than as structural defects that affect the channel’s water permeability. Therefore, proper plasma membrane insertion/trafficking is integral to proper AQP2 functioning and correct water molecule transport. A reagent that affects this process may consequently represent a potential target for modulating water absorption. Several studies from our group have revealed that besides cAMP- and cGMP-stimulated trafficking, AQP2 rapidly recycles between an intracellular pool and the plasma membrane under baseline (nonstimulated) conditions. In light of this constitutive pathway, steady-state accumulation of AQP2 at the plasma membrane may be mediated not only by an increase in exocytosis, as originally postulated by the shuttle hypothesis, but also by a reduction in endocytosis.

CLATHRIN-MEDIATED ENDOCYTOSIS OF AQP2

The clathrin-mediated pathway is one of the major routes of endocytosis in eukaryotic cells,
and is characterized by the selective internalization of proteins from the cell surface. An elaborate series of protein–protein interactions imparts selectivity on this highly dynamic process that involves the rapid assembly or disassembly of transient protein complexes. Both adenosine triphosphatases and guanosine triphosphatases (GTPases) modulate assembly of these complexes, requiring multiple interactions between clathrin, dynamin, heat shock cognate protein 70 (hsc70), the adaptor proteins AP2 and AP180, Esp15, and many other accessory proteins such as auxillin, endophilin, and amphiphysin. The presence of molecules later identified as AQP2 in clathrin-coated pits was first observed more than 20 years ago. More recently, endocytosis blockade achieved by transfecting a dominant-negative dynamin mutant into cultured cells was found to induce dramatic membrane accumulation of AQP2 (Fig. 3). Members of the heat-shock protein family (hsc70 and hsp70) were found to interact directly with AQP2 and regulate its trafficking. Immunogold electron microscopy showed that hsc70 colocalized with AQP2 in the plasma membrane. In addition, inhibition of endogenous hsc70 activity using a dominant-negative dynamin mutant also caused dramatic membrane accumulation of AQP2 in cells (Fig. 3). This suggests that hsc70 is likely to be involved in AQP2 endocytosis, although it cannot be ruled out that other biological functions are associated with the interaction of hsc/hsp70 and AQP2. A recent observation suggests that myelin and lymphocyte-associated protein is involved in regulated AQP2 trafficking by physically interacting with AQP2. It increases AQP2 plasma membrane expression by attenuating its internalization.

An interesting aspect of AQP2 endocytosis is that AQP2 constitutive recycling is independent of S256 phosphorylation. AQP2-S256D mutants are localized in the plasma membrane in the absence of VP stimulation whereas AQP2-S256A mutant expression is restricted to intracellular compartments. However, a cholesterol-depleting agent that inhibits endocytosis caused a large accumulation of AQP2 at the plasma membrane both in cell cultures and in isolated perfused rat kidney. Even AQP2-S256A mutants rapidly accumulated at the cell surface under these conditions, indicating that AQP2 dephosphorylated at S256 can also accumulate at the plasma membrane. Other observations additionally indicate that S256 phosphorylation alone is not sufficient to induce translocation of AQP2 to the cell surface. In Brattleboro rats, which display decreased levels of AQP2 abundance because of the lack of circulating VP, AQP2 is expressed mostly in intracellular pools despite the fact that a significant amount of AQP2 is phosphorylated at S256. VP treatment increased AQP2 cell surface expression but did not appear to increase its phosphorylation.

**AN ASSAY FOR AQP2 EXOCYTOSIS**

Although it was assumed initially that an increase of AQP2 exocytosis arises from AQP2 phosphorylation at S256, most assays to date measured only AQP2 cell surface accumulation...
rather than bona fide exocytosis. We have, however, recently shown that a burst of AQP2 exocytosis occurs during the first 15 to 20 minutes of VP stimulation (Fig. 4). This observation was made using a novel fluorescence-based assay that relies on expression of secreted soluble yellow fluorescence protein (ssYFP) that passively labels biosynthetic/post-Golgi vesicles. This assay provides an indirect but quantitative means to measure AQP2 exocytosis. In addition, a recent study has shown that VP stimulation increases AQP2 expression at the cell surface by inducing its accumulation in “endocytosis-resistant” membrane domains, indicating that although VP enhances AQP2 exocytosis, it significantly reduces AQP2 endocytosis. Increased expression of water channels at the cell surface through altered exocytotic and endocytotic activity already was suggested by mathematic modeling more than a decade ago before the molecular identification of AQPs.

It is well known that protein phosphorylation and dephosphorylation markedly affect the biological activity of proteins. As discussed earlier regarding the S256 residue, AQP2 phosphorylation plays an important role in AQP2 trafficking/membrane accumulation. Analysis of potential AQP2 phosphorylation sites in addition to S256 suggests the presence of putative sites for at least 4 kinases, namely PKG, protein kinase C, casein kinase II, and Golgi casein kinase in addition to PKA. The potential role of these phosphorylation sites is currently under investigation by our group as well as others.33,34,37,40-42 AQP2 targeting to the apical membrane may be achieved by manipulating its phosphorylation state, and pharmacological inhibition of phosphatase activity by okadaic acid is sufficient to increase expression of AQP2 at the plasma membrane of cultured cells.43 The events governing AQP2 phosphorylation and dephosphorylation undoubtedly will lead to the discovery of potential targets for the development of therapeutic reagents.

**POTENTIAL ROLE OF STATINS IN AQP2 TRAFFICKING**

By reducing cholesterol-containing atherogenic lipoproteins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) dramatically improve cardiovascular outcome. Studies performed on cell cultures of proximal tubular cells have provided evidence that statins reduce receptor-mediated endocytosis (RME) and that this is a consequence of statin-induced impaired prenylation and, therefore, membrane association, of one or more GTP-binding proteins that play a key role in RME.45,46 By reducing protein uptake, statins may even exert a renoprotective effect as suggested by animal models of kidney disease47 and by a meta-analysis of randomized trials.48 Various observations point to the pos-
sibility that statins might be used as a means to increase AQP2 cell surface expression. First, RME is a clathrin-mediated process, which requires the participation of several GTP-binding proteins, such as Rho, Rac, and Rab. Consistent with this, prenylation of the GTP-binding protein Rap1A was found to be reduced by statins in cultured proximal cells. An effect similar to that induced by statins on RME in proximal cells also may occur in CD cells and could affect AQP2 endocytosis. In this respect, statins may increase AQP2 cell surface expression by reducing its endocytosis. Second, low doses of statins were found to increase eNOS phosphorylation and activation in endothelial cells via increased Akt activation, and high doses of statins were found to increase eNOS protein synthesis through an increase of eNOS messenger RNA (mRNA) stability. Statins consequently may increase AQP2 cell surface expression by enhancing eNOS activity (see earlier). Third, high doses of statins were found to decrease Rho activity, a key player of actin reorganization that affects AQP2 trafficking, as discussed later. This effect may be attributed to inhibition of the geranylgeranylation and membrane localization of RhoA and by alterations in RhoA-dependent cell-signaling pathways, such as flk-1/KDR and Akt. Based on these observations, our laboratory currently is evaluating the role of statins in AQP2 trafficking with a view to developing potential novel therapies for the treatment of NDI.

**REARRANGEMENT OF CYTOSKELETAL COMPONENTS AND REGULATION OF SMALL G-PROTEINS**

Actin polymerization and depolymerization is a dynamic and tightly regulated process that plays an important role in protein trafficking. Actin reorganization is controlled by the Rho family of small GTP-binding proteins. This includes members of the RhoA-G, Cdc42, and Rac1 family that are activated after guanosine diphosphate is exchanged with GTP. The nucleotide exchange process is controlled by various proteins such as GTPase activating protein, guanine nucleotide exchange factors (GEFs), and guanine nucleotide dissociation inhibitors (GDI). Depolymerization of the actin network results in an increase of AQP2 expression at the cell surface whereas blockade of VP-induced AQP2 translocation in response to Rho activation was shown to be associated with increased actin polymerization. Thus, modulation of the actin cytoskeleton might represent a therapeutic approach for NDI, despite the omnipresence of Rho that makes this protein difficult to target specifically in CD principal cells. At the very least, a better understanding of the mechanisms that regulate cytoskeletal reorganization and AQP2 trafficking undoubtedly will help identify therapeutic targets whose modified activities may provide the basis for future therapies.

A shift of the equilibrium between V2R and prostaglandin E2 (PGE2) receptor stimulation affects the polymerization state of the actin cytoskeleton and consequently affects AQP2 trafficking to the plasma membrane. An increase of cAMP concentration after V2R activation results in Rho inhibition and the subsequent depolymerization of the actin cytoskeleton. PGE2, on the other hand, counteracts the VP-induced increase of osmotic water permeability in the renal CD. When PGE2 binds to the EP3 receptor, adenylate cyclase is inactivated, resulting in an increase of actin polymerization via Rho activation. PGE2 also may counteract the intrinsic actin reorganization capability of AQP2-bearing vesicles, as suggested by a recent observation that shows that AQP2 can interact directly with actin and SPA-1, a specific Rap GTPase activating protein.

**PROSTAGLANDINS AND URINE CONCENTRATION**

PGE2 is expressed abundantly in the kidney. It derives from arachidonic acid via cyclooxygenase (COX) and PGE synthetase (PGES) activities. Two COX isoforms, COX-1 and COX-2, are expressed in the kidney. Interestingly, COX-2 expression, which is known to be induced by physiologic stress, is increased in NDI patients. The development of selective COX inhibitors has raised several expectations. For example, rofecoxib (a COX-2 inhibitor) in combination with hydrochlorothiazide and a low-salt formula reduced urine volume in a 1-month-old male infant. However, COX-2 inhibitors should be used with extreme caution because of the high risk of developing myocardial infarction. The adverse effects associated with this
family of inhibitors suggest that more research should focus on the downstream effectors of the COX/PGE_2 signaling pathway.

Three isomers of PGES have been described recently. Interestingly, the microsomal PGE synthase 1 (mPGE_1) isoform is inducible and its expression is tightly related to COX-2 expression. mPGE_1 is expressed in the CD and is increased in type 2 diabetes. The role of mPGES in NDI has not been investigated fully but the recent availability of selective mPGE_1 inhibitors will allow us to investigate in-depth their potential therapeutic benefits. Several efforts have been made to develop PGE-receptor antagonists. Three of 4 PGE-receptor subtypes (prostaglandin E_2 receptor types 1, 3, and 4) are expressed in different regions of the kidney. EP_3 and EP_4 are expressed in the glomerulus, whereas EP_1 is undetectable in this region. However, 2 EP_3 isoforms are expressed in the CD. Some inhibitors of the PGE receptor have been developed that show interesting effects. An EP_3-selective antagonist has been shown to prevent the progression of nephropathy in streptozotocin-induced diabetic rats. In that study, Makino et al showed that aspirin, a nonselective COX inhibitor, has more beneficial effects on urine volume than a COX-selective antagonist. This result indicates that selective PGE-receptor antagonism may represent an efficient means of controlling water excretion and that every effort should be made to develop other PGE-receptor inhibitors that target other PGE-receptor isoforms such as EP_3.

Other alternative mechanisms recently have been reported to regulate AQP2 trafficking that may provide potential targets for future NDI therapies. Both bradykinin and Epac have been shown to increase AQP2 membrane expression. Bradykinin binds to the B2 receptor and leads to Rho activation, subsequently attenuating AQP2 trafficking by stabilizing polymerized actin. Bradykinin binds 2 receptor subtypes: B1 and B2. B2 is expressed constitutively in the renal CD whereas B1 expression is inducible. Both receptors share similar signaling pathways. However, little information is available on the role that the B1 receptor plays in NDI pathophysiology. The B1 receptor is associated with the progression of insulin-dependent diabetes and has a protective role in renal ischemia. The development of selective antagonists may help us to better understand its possible link to NDI. AQP2 trafficking is additionally affected by cAMP activation of the exchange protein (Epac). Epac can be activated selectively and directly by a cAMP analogue (8-pCPT-2’-O-McAMP). We speculate that activated Epac exchanges bound guanosine diphosphate with GTP in both Rap1 and Rap2 proteins, which play a role in cytoskeletal rearrangement.

MECHANISMS THAT REGULATE AQP2 WHOLE-CELL ABUNDANCE

In addition to controlled AQP2 expression at the cell surface, an increase of AQP2 whole-cell abundance represents an attractive approach for NDI therapy. Indeed, down-regulated AQP2 cell surface expression occurring in acquired NDI and in some cases of congenital NDI reflects down-regulated AQP2 abundance, which in some patients may limit the efficacy of strategies aimed simply at targeting presynthesized AQP2 to the cell surface. Although reduced AQP2 abundance is associated with reduced V2R activity in some cases of NDI, such as hypercalcaemia, other conditions of NDI appear to arise from VP-independent mechanisms. Recent evidence has shown that lithium-induced NDI is associated with an adenylyl cyclase–independent decrease of AQP2 mRNA expression, possibly resulting from decreased AQP2 transcription. In ureteral obstruction, VP-independent down-regulation of AQP2 abundance and cell surface expression was found to arise from increased COX-2 activity and PGE_2 synthesis. VP-independent mechanisms that increase AQP2 abundance may, thus, prove to be extremely valuable for designing new therapeutic strategies to treat NDI, as illustrated later.

In the kidney, the expression of AQP2 is restricted to the renal collecting system and is modulated by both VP and factors that act independently of VP. Several regulatory motifs that induce AQP2 transcriptional activity have been identified in the AQP2 promoter. The most well documented of these are activator protein-1 element and CRE sites that respectively bind cAMP-induced c-fos and the phosphorylated adenosine CRE binding protein.
In this respect, p-CREB plays a dual role in regulating AQP2 by inducing its accumulation at the cell surface and by enhancing AQP2 transcription. AQP2 abundance increases with interstitial tonicity and recent findings have shown that this up-regulation arises from increased transcription of the AQP2 gene. The tonicity-responsive enhancer binding protein (TonEBP) has been shown to play a key role in this event, most likely by binding to at least one TonE element present in the AQP2 promoter. Of particular interest to the present review, the stimulatory effect of TonEBP on AQP2 transcription was found to occur independently of VP. Moreover, a stimulatory effect of nuclear factor of activated T-cells c (NFATc), a transcription factor that belongs to the same family as TonEBP, on AQP2 transcription was shown in cultured renal cells together with cross-talk occurring between TonEBP and calcineurin–NFATc pathways that further enhance AQP2 transcription. Inhibition of TonEBP activity by calcineurin inhibitors, including cyclosporine A and its derivatives, has been shown to reduce AQP2 expression. Consequently, environmental signals that increase intracellular calcium, and calcineurin activation in particular, provide attractive targets for the promotion of AQP2 expression at the cell surface resulting from increased AQP2 whole-cell abundance.

Several pieces of evidence have shown that in addition to transcriptional regulation, AQP2 abundance also is modulated by posttranscriptional processing. AQP2 degradation is dependent on both lysosomal and proteasomal activity. Observations made from both in vitro and animal studies indicate that AQP2 protein degradation is associated inversely with changes in V2R activity. Moreover, both dihydrotachysterol-treated and fasted animals displayed a VP-independent decrease of AQP2 protein but not mRNA abundance, indicating that AQP2 protein degradation is regulated by both VP and factors acting independently of VP. In addition to controlled AQP2 protein degradation, enhanced translation of AQP2 mRNA may represent another means of increasing AQP2 whole-cell abundance. In vitro studies revealed a feedback mechanism that is dependent on transcriptional activity, that acts independently of AQP2 degradation, and that involves rapid synthesis of regulatory protein(s) that continuously reduce AQP2 mRNA translation. Aldosterone may enhance AQP2 protein abundance by alleviating such negative control on AQP2 mRNA translation. Further dissection of molecular elements involved in AQP2 degradation and mRNA translation may uncover potential targets delimiting therapies based on controlled AQP2 degradation/mRNA translation that would ultimately increase the expression of AQP2 at the cell surface.

SUMMARY

Recent advances in our understanding of the cell biology of AQP2 recycling and the signaling pathways that lead to the membrane accumulation of AQP2 in principal cells have opened up several possible strategies for inducing this process in the absence of conventional vasopressin signaling via its G-protein–coupled receptor, the V2R, which is defective in X-linked NDI. Furthermore, these strategies also may apply to other types of NDI, including some of the acquired forms. Superimposed on the need to stimulate AQP2 membrane trafficking is the requirement that sufficient AQP2 be expressed in principal cells of NDI patients to achieve effective therapy. We, therefore, also discuss some mechanisms that regulate AQP2 expression levels in target cells. Depending on the nature of the defect leading to NDI, it is likely that a combination of approaches, directed by the basic research endeavors that are ongoing in many laboratories, will be required to achieve a positive clinical outcome.

REFERENCES


